Gsk (GLAXF) Non-Current Deferred Tax Liability (2009 - 2026)

Gsk's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at -$393.7 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 22.63% year-over-year to -$393.7 million; the TTM figure through Mar 2026 stood at -$393.7 million (up 22.63% YoY), while the FY2025 annual figure was -$383.7 million, down 178.58% from the prior year.
• Non-Current Deferred Tax Liability was -$393.7 million for Q1 2026 at Gsk, down from -$387.1 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $490.3 million in Q4 2024 to a low of -$4.7 billion in Q1 2022.
• Historically, Non-Current Deferred Tax Liability has averaged -$528.8 million across 5 years, with a median of -$387.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability jumped 96.26% in 2022, then plunged 233.45% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $339.0 million in 2022, then grew by 13.87% to $386.0 million in 2023, then climbed by 27.02% to $490.3 million in 2024, then tumbled by 178.95% to -$387.1 million in 2025, then fell by 1.7% to -$393.7 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at -$393.7 million (Q1 2026), -$387.1 million (Q4 2025), and -$526.3 million (Q3 2025), per Business Quant data.